Kevin M Biglan

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Surrogate endpoints in Parkinson's disease research
    Kevin M Biglan
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Rochester, NY 14620, USA
    Curr Neurol Neurosci Rep 3:314-20. 2003
  2. doi request reprint Telemedicine for the care of nursing home residents with Parkinson's disease
    Kevin M Biglan
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Mov Disord 24:1073-6. 2009
  3. ncbi request reprint Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
    Kevin M Biglan
    University of Rochester, Department of Neurology, Rochester, NY 14620, USA
    Neurology 69:187-95. 2007
  4. doi request reprint Natural history of Huntington disease
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, Maryland6now with the University of Rochester Medical Center, Rochester, New York
    JAMA Neurol 70:1520-30. 2013
  5. doi request reprint Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
    Mov Disord 25:1652-9. 2010
  6. pmc Randomized controlled clinical trial of "virtual house calls" for Parkinson disease
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD 21287, USA
    JAMA Neurol 70:565-70. 2013
  7. pmc Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS
    Annie Killoran
    University of Rochester, Rochester, NY, USA
    Neurology 80:2022-7. 2013
  8. pmc Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely
    Amir Abdolahi
    Department of Community and Preventive Medicine, University of Rochester, School of Medicine and Dentistry, 265 Crittenden Blvd, CU 420644, Rochester, NY 14642, USA
    Parkinsonism Relat Disord 19:218-21. 2013
  9. ncbi request reprint Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
  10. doi request reprint A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
    Mov Disord 25:2128-35. 2010

Detail Information

Publications15

  1. ncbi request reprint Surrogate endpoints in Parkinson's disease research
    Kevin M Biglan
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Rochester, NY 14620, USA
    Curr Neurol Neurosci Rep 3:314-20. 2003
    ..Finally, the significant challenges that lie ahead for validating and interpreting surrogate endpoints in PD are addressed...
  2. doi request reprint Telemedicine for the care of nursing home residents with Parkinson's disease
    Kevin M Biglan
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Mov Disord 24:1073-6. 2009
    ..The visits resulted in improvements in motor and cognitive symptoms and suggest that telemedicine may be useful for delivering care to this population...
  3. ncbi request reprint Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
    Kevin M Biglan
    University of Rochester, Department of Neurology, Rochester, NY 14620, USA
    Neurology 69:187-95. 2007
    ..A secondary finding of the trial was a higher than anticipated development or worsening of somnolence and edema and development of hallucinations...
  4. doi request reprint Natural history of Huntington disease
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, Maryland6now with the University of Rochester Medical Center, Rochester, New York
    JAMA Neurol 70:1520-30. 2013
    ..Understanding the natural history of Huntington disease will inform patients and clinicians on the disease course and researchers on the design of clinical trials...
  5. doi request reprint Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
    Mov Disord 25:1652-9. 2010
    ..Providing subspecialty care via telemedicine for individuals with Parkinson's disease living remotely is feasible...
  6. pmc Randomized controlled clinical trial of "virtual house calls" for Parkinson disease
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD 21287, USA
    JAMA Neurol 70:565-70. 2013
    ..The burden of neurological disorders is increasing, but access to care is limited. Providing specialty care to patients via telemedicine could help alleviate this growing problem...
  7. pmc Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS
    Annie Killoran
    University of Rochester, Rochester, NY, USA
    Neurology 80:2022-7. 2013
    ..We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study...
  8. pmc Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely
    Amir Abdolahi
    Department of Community and Preventive Medicine, University of Rochester, School of Medicine and Dentistry, 265 Crittenden Blvd, CU 420644, Rochester, NY 14642, USA
    Parkinsonism Relat Disord 19:218-21. 2013
    ....
  9. ncbi request reprint Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
    ..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline...
  10. doi request reprint A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
    Mov Disord 25:2128-35. 2010
    ..Specialty care and improved education, in the clinic or through support groups, may enhance satisfaction and health care quality...
  11. ncbi request reprint Neuroprotection in Parkinson's disease: an elusive goal
    Kevin M Biglan
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA
    Semin Neurol 27:106-12. 2007
    ..Ultimately, overcoming the unique challenges of a heterogenous, slowly progressive disorder with multiple potential outcome measures will be necessary to identify treatments that have meaningful effects...
  12. pmc Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study
    Kevin M Biglan
    University of Rochester, Rochester, New York, USA
    Mov Disord 24:1763-72. 2009
    ..Longitudinal assessment will help inform whether motor items will be useful measures in preventive clinical trials...
  13. pmc Refining the diagnosis of Huntington disease: the PREDICT-HD study
    Kevin M Biglan
    Department of Neurology, University of Rochester Rochester, NY, USA
    Front Aging Neurosci 5:12. 2013
    ..A multidimensional method results in an earlier diagnosis with less motor and cognitive impairment than a motor diagnosis. Findings have implications for designing preventive trials and providing clinical care in prodromal HD...
  14. ncbi request reprint A review of pramipexole and its clinical utility in Parkinson's disease
    Kevin M Biglan
    University of Rochester, Department of Neurology, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Expert Opin Pharmacother 3:197-210. 2002
    ..In addition to its use in PD, pramipexole has shown some utility in the treatment of restless legs syndrome (RLS), depression and schizophrenia...